Recent insider open-market stock purchases demonstrate
continued confidence in the Company
CAESAREA, Israel, June 18,
2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of
the ProSense® System, a minimally-invasive cryoablation technology
that destroys tumors by freezing as an alternative to surgical
tumor removal, today announced the Company's management, will
participate in the Northland Capital Markets Virtual Growth
Conference on Tuesday, June 25,
2024.
"We have achieved our primary objectives for the first half of
2024, including the completion of the ICE3 trial and data results
submission to the FDA, and being able to share our progress with
investors at the Northland conference is timely as we firmly
believe in the value that we are creating," commented Eyal Shamir, Chief Executive Officer.
"Furthermore, we believe recent action taken by several members of
the Board and senior executives to purchase several tens of
thousands of shares in the open market demonstrate their continuing
confidence in the Company. Our entire team is optimistic
about IceCure's potential to offer minimally-invasive options
that are safe and just as effective as surgery for a growing number
of indications worldwide, including early-stage breast cancer."
The Company's Chief Executive Officer, Eyal Shamir, and Chief Financial Officer,
Ronen Tsimerman, will provide an
overview of IceCure Medical and review the latest developments and
catalysts, including the completion of the ICE3 trial and pending
De Novo Classification Request with the U.S. Food and Drug
Administration ("FDA") for marketing clearance of the ProSense®
Cryoablation System for the treatment of patients with early-stage,
low risk breast cancer. Interested investors can contact their
Northland Capital sales representative or Michael Polyviou at mpolyviou@evcgroup.com to
receive more information on the conference or to request a virtual
one-on-one meeting with IceCure's management team.
The Company qualifies as a foreign private issuer under the U.S.
federal securities laws and therefore its directors and executive
officers are not subject to certain reporting obligations,
including the filing of Statements of Changes of Beneficial
Ownership of Securities on Form 4 pursuant to Section 16 of the
Securities Exchange Act of 1934, as amended.
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive
treatment option to destroy tumors by freezing them. The system
uniquely harnesses the power of liquid nitrogen to create large
lethal zones for maximum efficacy in tumor destruction in benign
and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by accelerating
recovery, reducing pain, surgical risks, and complications. With
its easy, transportable design and liquid nitrogen utilization,
ProSense® opens that door to fast and convenient office-based
procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses: its
participation in the Northland Capital Markets Virtual Growth
Conference; and the potential of IceCure to offer
minimally-invasive options that are safe and just as effective as
surgery for a growing number of indications worldwide, including
early-stage breast cancer. Historical results of scientific
research and clinical and preclinical trials do not guarantee that
the conclusions of future research or trials will suggest identical
or even similar conclusions. Important factors that could cause
actual results, developments and business decisions to differ
materially from those anticipated in these forward-looking
statements include, among others: the Company's planned level of
revenues and capital expenditures; the Company's available cash and
its ability to obtain additional funding; the Company's ability to
market and sell its products; legal and regulatory developments in
the United States and other
countries; the Company's ability to maintain its relationships with
suppliers, distributors and other partners; the Company's ability
to maintain or protect the validity of its patents and other
intellectual property; the Company's ability to expose and educate
medical professionals about its products; political, economic and
military instability in the Middle
East, specifically in Israel; as well as those factors set forth in
the Risk Factors section of the Company's Annual Report on Form
20-F for the year ended December 31,
2022 filed with the SEC on March 29,
2023, and other documents filed with or furnished to the SEC
which are available on the SEC's website, www.sec.gov. The Company
undertakes no obligation to update these statements for revisions
or changes after the date of this release, except as required by
law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-to-provide-overview-and-share-recent-progress-at-northland-capital-markets-virtual-growth-conference-on-june-25-2024-302175465.html
SOURCE IceCure Medical